New assets have entered clinic, whilst dozens more have been disclosed, and recent investments such as, T-Therapeutics’ $91M Series A extension to advance their bispecific towards the clinic and Anocca’s SEK 440M raise, pinpoint how funding and portfolio decisions have the power to define the trajectory of the TCR field.

It is in this context that the 7th TCR-Based Therapies Summit returns to unite fellow biopharma experts in address shared challenges and to bridge the gap between promising clinical data and long-term, commercially viable TCR-based approaches.

Across three focused days, enter into open discussions, benchmark with peers, participate in practical problem-solving and hear new data in presentations led by Immunocore, Enara Bio, Regeneron, Eureka Therapeutics, T-Cypher Bio, Zelluna Immunotherapy, and Aethon Therapeutics.

Join us in empowering the community to shape a more durable, scalable, and commercially robust future for TCR-based therapies.

To know more visit: https://ter.li/uhpzx3